Economic burden of moderate to severe irritable bowel syndrome with constipation in six European countries

BackgroundIrritable bowel syndrome with predominant constipation (IBS-C) is a complex disorder with gastrointestinal and nervous system components. The study aim was to assess the economic burden of moderate to severe IBS-C in six European countries (France, Germany, Italy, Spain, Sweden and the UK)...

Full description

Authors: Tack, J; Stanghellini, V; Mearin, F; Yiannakou, Y; Layer, P; Coffin, B; Simren, M; Mackinnon, J; Wiseman, G; Marciniak, A; Bouchoucha; Ducrotte; Macaigne; Mion; Schneider; Le Sidanier; Tardy; Zerbib; Andresen; Bischoff; Jander; Jung; Krammer; Langhorst; Omankowsky; Schiefke; Steuer; Van der Voort; Von Arnim; Annese; Cuomo; De Angelis; Di Mario; Di Stefano; Ferrini; Gasbarrini; Giaccobe; Marchi; Marzio; Repici; Savarino; Angos; Berdier; Brotons; Caballero-Plasencia; Clave; Fort; Garcia; Gomez; Martinez; Perello; Rey; Sanchez-Antolin; Serra; Tantina; Toran; Ekesbo; Hellstrom; Kjellstrom; Lindberg; Walter; Arebi; Bridger; Butt; Emmanuel; Eugenicos; Kaushik; Millar; Sanders; Whorwell
Format: Article
Status:Published version
Publication date:2019
Country:España
Institution:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
Repository:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
OAI Identifier:oai:iibsantpau.fundanetsuite.com:p13821
Online Access:https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=13821
Access Level:Open access
Keyword:IBS
IBS-C
Economic analysis
Healthcare resource utilisation
Europe
Summary:BackgroundIrritable bowel syndrome with predominant constipation (IBS-C) is a complex disorder with gastrointestinal and nervous system components. The study aim was to assess the economic burden of moderate to severe IBS-C in six European countries (France, Germany, Italy, Spain, Sweden and the UK).MethodsAn observational, one year retrospective-prospective (6months each) study of patients diagnosed in the last five years with IBS-C (Rome III criteria) and moderate to severe disease at inclusion (IBS Symptom Severity Scale score175). The primary objective was to assess the direct cost to European healthcare systems.ResultsFive hundred twenty-five patients were included, 60% (range: 43.1-78.8%) suffered from severe IBS-C. During follow-up 11.1-24.0% of patients had a hospitalisation/emergency room (ER) visit, median stay range: 1.5-12.0days and 41.1-90.4% took prescription drugs for IBS-C. 21.4-50.8% of employed patients took sick leave (mean: 11.6-64.1days). The mean annual direct cost to the healthcare systems was Euro937.1- Euro2108.0. The total direct cost (combined costs to healthcare systems and patient) for IBS-C was Euro1421.7-Euro2487.1.ConclusionsIBS-C is not a life-threatening condition; however, it has large impact on healthcare systems and society. Direct and indirect costs for moderate to severe IBS-C were high with the largest direct cost driver being hospitalisations/ER visits.

Similar Items